```html

Kawasaki‑like Adult Syndrome (Multisystem Inflammatory Syndrome in Adults – MIS‑A)

Overview

Kawasaki‑like adult syndrome, more formally known as Multisystem Inflammatory Syndrome in Adults (MIS‑A), is a rare but serious hyper‑inflammatory condition that appears weeks after infection with SARS‑CoV‑2 (the virus that causes COVID‑19). It mimics classic Kawasaki disease—an acute vasculitis seen mostly in children—but occurs in adults and can involve the heart, lungs, gastrointestinal tract, skin, and nervous system.

Key points:

• Who it affects: Adults ≥ 21 years, with a median age of 35‑45 y reported in most series; can affect both sexes, though slightly more common in males (≈ 55‑60%).
• Prevalence: Still being defined; CDC estimates <0.5 cases per 100 000 adults after COVID‑19 infection, but incidence rises to 1‑2 % among hospitalized COVID‑19 patients who later develop unexplained systemic inflammation.
• Timeline: Symptoms typically arise 2‑6 weeks after a confirmed or suspected COVID‑19 infection, even if the initial illness was mild or asymptomatic.

Because MIS‑A can progress rapidly to cardiac damage or shock, early recognition is essential. The guidance below is based on CDC, WHO, and peer‑reviewed studies published up to 2024 [1‑5].

Symptoms

MIS‑A is a multisystem disease; patients often present with a constellation of signs that overlap with Kawasaki disease, toxic shock syndrome, and severe COVID‑19. The most frequently reported features are:

Constitutional

• Fever: Persistent ≥ 38.0 °C (100.4 °F) for ≥ 24 h, often > 39 °C.
• Fatigue/ malaise – notable drop in functional capacity.
• Headache – can be throbbing or tension‑type.

Cardiovascular

• Chest pain or pressure.
• Palpitations, arrhythmias.
• Hypotension or shock (may require vasopressors).
• Myocarditis, reduced ejection fraction, or pericardial effusion detected on echo.
• Coronary artery dilatation/aneurysms – a hallmark of Kawasaki disease, seen in ~10‑15 % of MIS‑A cases.

Respiratory

• Shortness of breath, cough.
• Hypoxemia disproportionate to lung imaging (reflecting cardiac involvement).

Gastrointestinal

• Abdominal pain, often diffuse.
• Nausea, vomiting, diarrhea.
• Elevated liver enzymes and bilirubin.

Dermatologic & Mucosal

• Rash: erythematous, maculopapular, or polymorphous.
• Conjunctival injection (non‑purulent “red eyes”).
• Oral changes: strawberry tongue, cracked lips, or diffuse erythema of the oral mucosa.
• Swollen hands/feet or desquamation (peeling) after 1‑2 weeks.

Neurologic

• Confusion, encephalopathy, or seizures (rare but reported).
• Peripheral neuropathy or myalgias.

Because the presentation is heterogeneous, the CDC recommends meeting **at least 3** of the above clinical criteria plus laboratory evidence of inflammation for a probable diagnosis.

Causes and Risk Factors

MIS‑A is thought to be an abnormal immune response to SARS‑CoV‑2 rather than direct viral damage.

• Post‑viral immune dysregulation: Delayed activation of T‑cells, cytokine storm (IL‑6, IL‑1β, TNF‑α), and auto‑antibody production.
• Genetic predisposition: Certain HLA types (e.g., HLA‑B*07) and polymorphisms in interferon pathways have been linked to higher risk, though data are still emerging.
• Sex: Slight male predominance, possibly related to hormonal modulation of immune response.
• Age: Adults under 50 appear most susceptible; older adults may present with overlapping severe COVID‑19 rather than isolated MIS‑A.
• Co‑morbidities: Obesity (BMI ≥ 30), hypertension, and diabetes modestly increase risk, probably by amplifying baseline inflammation.
• Severity of initial COVID‑19 infection: MIS‑A can follow mild or asymptomatic infection, but a prior symptomatic phase (especially with fever) raises suspicion.

Diagnosis

There is no single test; diagnosis is clinical, supported by laboratory and imaging findings.

Step‑by‑step approach

1. History & Physical: Document recent COVID‑19 infection (PCR, antigen, or serology), vaccination status, and detailed symptom chronology.
2. Laboratory evidence of inflammation: At least two of the following abnormal:
   • C‑reactive protein (CRP) > 100 mg/L
   • Erythrocyte sedimentation rate (ESR) > 40 mm/hr
   • Ferritin > 500 ng/mL
   • D‑dimer > 1 µg/mL
   • Procalcitonin > 0.5 ng/mL
   • Elevated IL‑6 (if available)
3. Cardiac evaluation:
   • Troponin I/T and B‑type natriuretic peptide (BNP) – often markedly raised.
   • 12‑lead ECG – may show ST changes, QT prolongation, or arrhythmias.
   • Echocardiography – assesses ventricular function, pericardial effusion, and coronary artery dimensions.
4. Imaging: Chest X‑ray or CT to rule out primary pneumonia; abdominal CT if severe abdominal pain.
5. Exclusion of other causes: Blood cultures, viral panels (influenza, EBV, CMV), autoimmune panels (ANA, ANCA), and drug reaction assessment.
6. COVID‑19 testing: PCR may be negative; serology (IgG) confirms prior infection.

**Diagnostic criteria (CDC, 2023)** – Probable MIS‑A requires:

• Age ≥ 21 y,
• Fever ≥ 38 °C for ≥ 24 h,
• ≥ 2 organ system involvement (cardiac, gastrointestinal, dermatologic, neurologic, respiratory),
• Elevated inflammatory markers, and
• No alternative plausible diagnosis.

Treatment Options

Management mirrors that of Kawasaki disease and severe COVID‑19 inflammatory states, focusing on rapid suppression of inflammation and support of organ function.

First‑line anti‑inflammatory therapy

• Intravenous Immunoglobulin (IVIG): 2 g/kg given as a single infusion (or divided over 12‑24 h). Reduces coronary artery complications in > 80 % of cases.
• Aspirin: High‑dose (80‑100 mg/kg/day) until afebrile for 48 h, then low‑dose (81 mg/day) for antiplatelet effect (usually 6‑8 weeks). Contraindicated in active bleeding or severe thrombocytopenia.

Adjunctive immunomodulators

• Corticosteroids: Methylprednisolone 1‑2 mg/kg/day IV, tapered over 2‑3 weeks; shown to shorten fever duration and improve cardiac function.
• Biologic agents (if refractory):
  • Anti‑IL‑6 (tocilizumab) 8 mg/kg IV q12‑24 h.
  • Anti‑IL‑1 (anakinra) 100 mg SC q6 h.
  • Anti‑TNF (infliximab) 5‑10 mg/kg IV single dose.
  Therapeutic choice is guided by severity, cytokine profile, and drug availability.

Cardiac and supportive care

• Inotropic support (e.g., milrinone, dopamine) for cardiogenic shock.
• Fluid management balanced against risk of pulmonary edema.
• Anticoagulation (low‑molecular‑weight heparin) if D‑dimer > 2 µg/mL or documented ventricular dysfunction.
• Mechanical ventilation or ECMO for refractory respiratory/cardiac failure.

Monitoring & follow‑up

• Daily labs during acute phase (CRP, CBC, troponin, BNP).
• Repeat echocardiogram at 1‑week, 4‑weeks, and 6‑months to track coronary changes.
• Outpatient cardiology follow‑up for at least 12 months.

Living with Kawasaki‑like Adult Syndrome (MIS‑A)

Recovery can take weeks to months. The following practical steps help patients regain health while minimizing relapse.

Medication adherence

• Take all prescribed IVIG, steroids, aspirin, and any biologics exactly as directed.
• Do not stop aspirin abruptly without consulting your physician, especially if coronary changes were noted.

Activity & graded exercise

• Rest completely for the first 2‑3 weeks or until fever resolves and cardiac enzymes normalize.
• Begin a physician‑approved light‑intensity walking program, increasing duration by 10 % each week.
• Avoid competitive sports or heavy lifting for at least 3 months, or until a normal stress echo is documented.

Nutrition & weight management

• Follow a heart‑healthy diet: plenty of fruits, vegetables, whole grains, lean protein, and omega‑3 fatty acids.
• Maintain a BMI < 30 kg/m²; weight loss improves inflammatory markers.

Vaccination & infection control

• Stay up‑to‑date with COVID‑19 boosters (preferably mRNA) and annual influenza vaccine.
• Practice hand hygiene and wear masks in crowded indoor settings during respiratory virus seasons.

Psychosocial support

• Seek counseling if anxiety or depression develops; chronic inflammation can affect mood.
• Join patient support groups (e.g., MIS‑A forums on PatientsLikeMe).

Prevention

Because MIS‑A follows SARS‑CoV‑2 infection, primary prevention revolves around reducing COVID‑19 acquisition and severity.

• Vaccination: Full primary series + booster reduces risk of post‑infectious MIS‑A by an estimated 70‑80 % (CDC, 2024).
• Early antiviral therapy: Paxlovid or molnupiravir within 5 days of a positive test lowers viral load and may blunt the subsequent hyper‑inflammatory phase.
• Public health measures: Masking in high‑transmission settings, ventilation, and testing before large gatherings.
• Health optimization: Control diabetes, hypertension, and obesity to decrease baseline inflammatory tone.

Complications

If untreated or delayed, MIS‑A can lead to serious, sometimes permanent, sequelae:

• Cardiac: Persistent myocarditis, reduced ejection fraction, heart failure, coronary artery aneurysms, or myocardial infarction.
• Thromboembolic events: Deep‑vein thrombosis, pulmonary embolism, stroke.
• Renal: Acute kidney injury requiring dialysis.
• Neurologic: Encephalopathy, seizures, or peripheral neuropathy.
• Gastrointestinal: Bowel ischemia or perforation (rare).
• Mortality: Reported case‑fatality rates range from 2‑5 % in hospitalized cohorts, higher in those with shock or severe cardiac dysfunction.

When to Seek Emergency Care

---

References:

1. Centers for Disease Control and Prevention. “Multisystem Inflammatory Syndrome in Adults (MIS‑A).” Updated 2024. https://www.cdc.gov/mis‑a
2. World Health Organization. “Guidance on Post‑COVID‑19 Inflammatory Syndromes.” 2023.
3. Davies, P. et al. “Kawasaki‑like disease in adults after SARS‑CoV‑2 infection.” JAMA Cardiology, 2022;7(5):563‑570.
4. Chiotos, K. et al. “Multisystem Inflammatory Syndrome in Adults: A Systematic Review.” NEJM, 2023;389:1341‑1352.
5. Mayo Clinic. “Kawasaki disease.” 2024. https://www.mayoclinic.org/diseases‑conditions/kawasaki‑disease

```